Viridian Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Steve Mahoney

Algemeen directeur

US$13.0m

Totale compensatie

Percentage CEO-salaris	0.9%
Dienstverband CEO	less than a year
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Steve Mahoney's beloning veranderd ten opzichte van Viridian Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$228m
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Compensatie versus markt: De totale vergoeding ($USD 13.02M ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 2.30M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Steve te vergelijken met de prestaties van het bedrijf.

CEO

Steve Mahoney (53 yo)

less than a year

Tenure

US$13,022,654

Compensatie

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	0.028% $ 493.3k
Seth Harmon	Senior VP of Finance and Accounting	1.1yrs	US$6.67m	0.0013% $ 23.1k
Thomas Beetham	Chief Operating Officer	less than a year	US$5.17m	0.0079% $ 138.3k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Vahe Bedian	Co-Founder & Scientific Advisor	no data	geen gegevens	geen gegevens
Jennifer Tousignant	Chief Legal Officer	less than a year	geen gegevens	geen gegevens
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Melissa Manno	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Anthony Casciano	Chief Commercial Officer	1.5yrs	geen gegevens	geen gegevens
Thomas Ciulla	Chief Medical Officer	1.8yrs	geen gegevens	0.0010% $ 17.6k

1.0yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0K1R wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Mahoney	CEO, President & Director	less than a year	US$13.02m	0.028% $ 493.3k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Arlene Morris	Independent Director	6.8yrs	US$477.83k	0% $ 0
Victor Ambros	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Stefanie Dimmeler	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Jeffery Molkentin	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Eva van Rooij	Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Tomas Kiselak	Independent Chairperson of Board	4yrs	US$503.83k	0% $ 0
Jennifer Moses	Independent Director	3.3yrs	US$467.83k	0% $ 0
Peter Harwin	Independent Director	4yrs	US$471.83k	0% $ 0

4.0yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0K1R wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Viridian Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director recently bought US$499k worth of stock

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Recent updates

CEO, President & Director recently bought US$499k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

First half 2024 earnings released: US$1.82 loss per share (vs US$2.88 loss in 1H 2023)

New major risk - Revenue and earnings growth

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought US$101k worth of stock

President recently bought US$160k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

High number of new and inexperienced directors

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$1.26 loss in 3Q 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

High number of new and inexperienced directors

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

High number of new and inexperienced directors

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd